Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
Purple Biotech (NASDAQ:PPBT) was downgraded by analysts at
Wall Street Z
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification
Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance [Yahoo! Finance]